Cleviprex Emulsion
Product Images NDC 18124-011

15 FDA label images from Fresenius Kabi Austria Gmbh · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Cleviprex (NDC 18124-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Austria Gmbh, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clevidipine Structure And Formula (Cle0o 0000 01)

Clevidipine Structure And Formula (Cle0o 0000 01)
Chemical structure of clevidipine, the active ingredient in Cleviprex .5 mg/mL intravenous emulsion. The diagram shows the molecular configuration relevant to this antihypertensive drug product by Fresenius Kabi Austria GmbH.*
FDA Label Image

Figure 1. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-1 (preoperative) (Cle0o 0000 02)

Figure 1. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-1 (preoperative) (Cle0o 0000 02)
A line graph comparing the mean changes in systolic blood pressure over time in minutes for clevidipine versus placebo. The graph shows a decrease in systolic blood pressure for clevidipine while the placebo line remains relatively stable over the 30-minute time period.*
FDA Label Image

Figure 2. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-2 (postoperative) (Cle0o 0000 03)

Figure 2.  Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-2 (postoperative) (Cle0o 0000 03)
A line graph comparing mean systolic blood pressure changes over time between placebo and clevidipine infusion. The x-axis represents time in minutes up to 36 minutes, and the y-axis shows the change from baseline in mm Hg, illustrating a greater decrease in blood pressure with clevidipine compared to placebo.*
FDA Label Image

Figure 3. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-1 (preoperative) (Cle0o 0000 04)

Figure 3.  Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-1 (preoperative) (Cle0o 0000 04)
A line graph comparing mean plasma concentration of clevidipine versus placebo over time in minutes, showing data points for both treatments from 0 to 30 minutes.*
FDA Label Image

Figure 4. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-2 (postoperative) (Cle0o 0000 05)

Figure 4.  Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-2 (postoperative) (Cle0o 0000 05)
A line graph displaying the mean change from baseline measured over 30 minutes, comparing Cleviprex (clevidipine) to placebo. The x-axis represents time in minutes, and the y-axis shows the mean change from baseline, illustrating the differences in response between Cleviprex and placebo groups throughout the time course.*
FDA Label Image

Figure 5. Mean Percent Change In Sbp (%) During The First 30 Minutes Of Infusion, Velocity (severe Hypertension) (Cle0o 0000 06)

Figure 5.  Mean Percent Change In Sbp (%) During The First 30 Minutes Of Infusion, Velocity (severe Hypertension) (Cle0o 0000 06)
A line graph showing mean percentage change in a variable over 30 minutes, labeled with clevidipine. The horizontal axis represents time in minutes from 0 to 30, and the vertical axis represents mean percent change from baseline decreasing steadily over time.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
The label for Cleviprex (clevidipine) injectable emulsion, 25 mg per 50 mL vial (0.5 mg/mL), from Fresenius Kabi Austria GmbH. The label includes dosing instructions for intravenous use only, emphasizing single-patient use and time vial is stable after opening. It contains safety and administration information, barcodes, and regulatory symbols.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Packaging label for Cleviprex (clevidipine) injectable emulsion, 25 mg per 50 mL (0.5 mg/mL), for intravenous use. The label indicates it is a single-use vial distributed by Fresenius Kabi Austria GmbH and includes dosing and storage instructions. The label emphasizes that Cleviprex is contraindicated in patients with allergies to soy or eggs and must not be frozen.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Cleviprex 0.5 mg/mL (clevidipine) injectable emulsion carton label for intravenous use. The label indicates a strength of 25 mg per 50 mL vial, packaged as 10 single-use vials. The labeler is Fresenius Kabi Austria GmbH, with branding from The Medicines Company. Storage instructions and a barcode are also present on the label.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Cleviprex 0.5 mg/mL injectable emulsion label showing the product name and dosage strength (50 mg/100 mL). The label includes usage instructions, storage directions, and the labeler Fresenius Kabi Austria GmbH. It specifies that the product is for intravenous use only in a 100 mL single-use vial and instructs to invert the vial gently several times before use.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Cleviprex (clevidipine) injectable emulsion 50 mg/100 mL (0.5 mg/mL) packaging label for intravenous use. The label features dosage information, storage instructions, manufacturer details (The Medicines Company, Fresenius Kabi Austria), and warnings including allergen and contamination precautions. It is a single-use emulsion vial, with usage instructions and a prominent barcode.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Packaging label for Cleviprex injectable emulsion containing clevidipine 50 mg per 100 mL (0.5 mg/mL) for intravenous use. The label indicates 10 single-use vials per carton, labeled for Rx only. The product is distributed by Fresenius Kabi Austria GmbH. Storage instructions and a barcode are also visible.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Label for Cleviprex (clevidipine) injectable emulsion, showing strength 125 mg per 250 mL (0.5 mg/mL). The label includes instructions such as 'Invert Vial Gently Several Times Before Use' and warnings for single patient use and disposal. It also displays the NDC 65293-005-25 and the labeler Fresenius Kabi Austria GmbH. The emulsion is indicated for intravenous use.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Packaging label for Cleviprex (clevidipine) injectable emulsion, 125 mg/250 mL (0.5 mg/mL) strength. The label indicates it is a single-use vial for intravenous use only, manufactured by Fresenius Kabi Austria GmbH for The Medicines Company. It includes storage instructions, contraindication for patients allergic to soy or eggs, and a caution regarding microbial growth and use.*
FDA Label Image

Package Label (Principal Display Panel)

Package Label (Principal Display Panel)
Packaging label for Cleviprex injectable emulsion containing clevidipine at 0.5 mg/mL strength, total 125 mg per 250 mL. The label specifies 4 single-use vials for intravenous use only, prescription only. It includes manufacturer information, storage instructions, dosage warnings, and a barcode. The labeler is Fresenius Kabi Austria GmbH.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.